PBM (Psyence Biomedical) Pre-Tax Income : $-46.59 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Psyence Biomedical's pretax income for the six months ended in Sep. 2024 was $2.96 Mil. Its pretax income for the trailing twelve months (TTM) ended in Sep. 2024 was $-46.59 Mil. Psyence Biomedical's pretax margin was %.

Psyence Biomedical Pre-Tax Income Historical Data

The historical data trend for Psyence Biomedical's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Pre-Tax Income Chart

Psyence Biomedical Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Pre-Tax Income

-1.86

-3.21

-51.16

Psyence Biomedical Semi-Annual Data
	Mar21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Pre-Tax Income	Get a 7-Day Free Trial			-0.64	-2.57	-1.61	-49.55	2.96

Competitive Comparison of Psyence Biomedical's Pre-Tax Income

For the Biotechnology subindustry, Psyence Biomedical's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Psyence Biomedical's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's Pre-Tax Income falls into.

Save Embed

;

Save Embed

;

Psyence Biomedical Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Psyence Biomedical's Pretax Income for the fiscal year that ended in Mar. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-44.233	+	-6.875	+	-0.053	+	0.002	+	-7.105427357601E-15
	=	-51.16

Psyence Biomedical's Pretax Income for the quarter that ended in Sep. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.933	+	4.898	+	-0.004	+	0	+	4.4408920985006E-16
	=	2.96

Pre-Tax Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-46.59 Mil.

Psyence Biomedical (NAS:PBM) Pre-Tax Income Explanation

Psyence Biomedical's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	2.961	/	0
	=	%

Psyence Biomedical Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1

Website

https://www.psyence.com

Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.